Safety and efficacy of alpha-lipoic acid oral supplementation in the reduction of pain with unknown etiology: A monocentric, randomized, double-blind, placebo-controlled clinical trial - 13/11/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Introduction |
Extensive evidence suggests that alpha-lipoic acid (ALA) is effective in diabetic neuropathy pain management. However, little is known on its safety and efficacy in reducing idiopathic pain in normoglycemic subjects. The aim of this study was to evaluate ALA food supplement safety and efficacy in the reduction of different forms of idiopathic pain.
Methods |
Two-hundred and ten normoglycemic adults suffering from idiopathic pain (i.e. 57 subjects with primitive neuropathic pain, 141 subjects with arthralgia with unknown etiology, and 12 subjects with idiopathic myalgia) were randomized to receive placebo, 400 mg/day, or 800 mg/day of ALA. Participants underwent two visits (at baseline = t0, and after 2 months = t1) in which two validated questionaries for pain (numerical rating scale [NRS] and visual analogue scale [VAS]) were collected; fasting blood glucose assessment, adverse effects, and renal and hepatic toxicity were also monitored.
Results |
At t1, none of subjects treated with ALA reported a decreased glycemia or adverse effects. The treated subjects showed a significant reduction in NRS (p < 0.001) while the placebo group did not show any NRS reduction (p = 0.86). Similar results were also obtained for VAS. Statistical analysis aimed at detecting possible differences in NRS and VAS scores among treatment groups based on the source of pain did not reveal any significant effect.
Conclusions |
Since the management of idiopathic pain is challenging for physicians, the use of ALA food supplements could be a feasible option, based on its safety and efficacy compared to commonly-used analgesic drugs.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Alpha-lipoic acid (ALA) is safe and effective in pain management. |
• | Subjects receiving ALA showed a reduction in NRS compared to placebo group. |
• | Subjects receiving ALA showed a reduction in VAS compared to placebo group. |
• | The use of ALA could be a feasible option for idiopathic pain management. |
Abbreviations : ALA, AMPK, ARs, BMI, CRE, CRF, DHLA, EFSA, GLUT4, HOMA-IR, IAA, IAS, IASP, ICD, IPS, IR, IRS-1, LMM, NDA, NRS, NSAID, SGOT, SGPT, SNRIs, VAS, WHO
Keywords : Alpha-lipoic acid, Idiopathic pain, Food supplement, Safety, Efficacy
Plan
Vol 144
Article 112308- décembre 2021 Retour au numéro
Article précédent
- Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation
- Ying Jin, Xueqin Chen, Zizheng Gao, Xiaofei Shen, Huangxi Fu, Zezheng Pan, Hao Yan, Bo Yang, Qiaojun He, Zhifei Xu, Peihua Luo
- Exosomes-mediated phenotypic switch of macrophages in the immune microenvironment after spinal cord injury
- Peng Peng, Hao Yu, Cong Xing, Bo Tao, Chao Li, Jingyuan Huang, Guangzhi Ning, Bin Zhang, Shiqing Feng
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?